Epstein barr virus hemophagocytic lymphohistiocytosis related to rituximab use and immunopathogenetic insights

详细信息    查看全文

• 作者：Sotirios G. Papageorgiou ; ^a ; ¹ ; ^{sotirispapageorgiou@hotmail.com} ; Sotirios Tsiodras^b ; ¹ ; Georgios Siakallis^b ; Efthimia Bazani^a ; Aris Spathis^c ; Garyfalia Poulakou^b ; Penelope Korkolopoulou^d ; Ioannis Panayiotides^c ; Vasiliki Pappa^a
• 关键词：Epstein barr virus ; EBV ; Hemophagocytic lymphohistiocytosis ; Anti-CD 20 ; Rituximab ; Hodgkin lymphoma ; Richter&rsquo ; s
• 刊名：Pathology - Research and Practice
• 出版年：2016
• 出版时间：December 2016
• 年：2016
• 卷：212
• 期：12
• 页码：1194-1198
• 全文大小：1868 K
• 卷排序：212

文摘

Anti-CD20-based chemo-immunotherapeutic regimens have been suggested to assist in the management of Epstein-Barr virus (EBV)-induced hemophagocytic lymphohistiocytosis (HLH) and EBV-associated post-transplant lymphoproliferative disorders (EBV-PTLD), by reducing EBV viral load and EBV-induced inflammation.Herein we report a fatal EBV-related HLH in the context of Hodgkin lymphoma (HL)-like Richter’s transformation of B chronic lymphocytic leukemia (B-CLL), two months after rituximab treatment. The complex balance between EBV driven T-cell stimulation and immunosuppressive therapy in the context of multiple immune deficits is discussed.